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(57) ABSTRACT 
A group I intron-derived ribozyme Which binds RNA in 
trans, excises an internal segment from Within the RNA, and 
splices the remaining 5' and 3' ends of the RNA back 
together (the trans-excision-splicing reaction) is disclosed. 
The excised segment can be as long as 28 nucleotides, or 
more, and as little as one nucleotide. The ribozymes of the 
invention are easily modi?ed to alter their sequence speci 
?city. Such ribozymes represent a neW and potentially 
powerful class of generally adaptable genetic therapeutics. 
8 Claims, 8 Drawing Sheets 
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TRANS-EXCISION-SPLICING RIBOZYME 
AND METHODS OF USE 
This application claims priority to Provisional Applica 
tion Ser. No. 60/431,965, ?led Dec. 10, 2002. 
FIELD OF THE INVENTION 
This invention relates generally to the ?eld of genetic 
therapeutics. More particularly, the invention relates to a 
trans-excision-splicing riboZyme having adaptable sequence 
recognition speci?city that provides a poWerful tool for 
genetic therapies. 
BACKGROUND OF THE INVENTION 
The discovery of catalytic RNA fundamentally changed 
the course of science. The subsequent realiZation that cata 
lytic RNAs could be tailored to suit individual needs has 
been nothing less than inspiring. Indeed, the past ten years 
has seen the creative development of numerous RNA cata 
lysts. Concurrently, the diversity of applications for these 
catalytic RNAs has been escalating. For example, catalytic 
RNAs are being developed for detection protocols, for 
therapeutic intervention of diseases, and for use as bio 
chemical tools. As We continue to exploit the steadily 
increasing knowledge base of RNA structure, folding, and 
catalysis, designing and applying novel and e?‘ective RNA 
catalysts is becoming more and more tractable. 
RiboZymes are RNA molecules having an enZymatic 
activity, Which enables the riboZyme to repeatedly cleave 
other separate RNA molecules in a nucleotide base 
sequence-speci?c manner. Such enZymatic RNA molecules 
can be targeted to virtually any RNA transcript, and ef?cient 
cleavage achieved in vitro. Kim et al., 84 Proc. Natl. Acad. 
Sci. USA 8788, 1987; Haselolf and Gerlach, 334 Nature 
585, 1988; Cech, 260 JAMA 3030, 1988; and Je?‘eries et al., 
17 Nucleic Acids Research 1371, 1989. 
RiboZymes act by ?rst binding to a target RNA. Such 
binding occurs through the target RNA binding portion of a 
riboZyme, Which is held in close proximity to an enZymatic 
portion of the RNA that acts to cleave the target RNA. Thus, 
the riboZyme ?rst recogniZes and then binds a target RNA 
through complementary base-pairing, and once bound to the 
correct site, acts enZymatically to cut the target RNA. 
Strategic cleavage of such a target RNA destroys its ability 
to direct synthesis of an encoded protein. After a riboZyme 
has bound and cleaved its RNA target it is released from that 
RNA to search for another target and can repeatedly bind 
and cleave neW targets. 
Six basic varieties of naturally-occurring enZymatic 
RNAs are knoWn presently. Each can catalyZe the hydrolysis 
of RNA phosphodiester bonds in trans (and thus can cleave 
other RNA molecules) under physiological conditions. In 
general, enZymatic nucleic acids act by ?rst binding to a 
target RNA. Such binding occurs through the target binding 
portion of an enZymatic nucleic acid Which is held in close 
proximity to an enZymatic portion of the molecule that acts 
to cleave the target RNA. Thus, the enzymatic nucleic acid 
?rst recogniZes and then binds a target RNA through 
complementary base-pairing, and once bound to the correct 
site, acts enZymatically to cut the target RNA. Strategic 
cleavage of such a target RNA Will destroy its ability to 
direct synthesis of an encoded protein. After an enzymatic 
nucleic acid has bound and cleaved its RNA target, it is 
released from that RNA to search for another target and can 
repeatedly bind and cleave neW targets. 
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A catalytic RNA that can excise a speci?c RNA sequence 
out of a larger RNA (the trans-excision-splicing reaction), 
although not previously discovered or engineered, Would be 
very useful as a biochemical tool and also as a potential neW 
therapeutic strategy. For example, multiple turnover cata 
lytic RNAs, or riboZymes, With this activity could be used to 
excise a disease-causing RNA region out of a native tran 
script, to remove a premature stop codon, or to restore a 
frameshift mutation, for example. 
SUMMARY OF THE INVENTION 
In one aspect of the invention there is provided a trans 
excision-splicing riboZyme comprising at least tWo recog 
nition elements that are complementary to a target sequence 
Within a substrate, Wherein the target sequence is not 
complementary to native recognition elements, Wherein at 
least one of said recognition elements stabiliZes binding of 
the riboZyme to a trans-excision splicing (TES) reaction 
intermediate product, and Wherein the riboZyme catalyZes a 
speci?c excision of the target sequence and splices the 5' end 
of the substrate created by the excision to an 00G of the 3' end 
of the substrate created by the excision. 
In another aspect of the invention there is provided a 
polynucleotide molecule comprising a riboZyme expression 
cassette that is capable of being stably inserted into a host, 
the cassette comprising a promoter operably-linked to a 
nucleotide sequence encoding a trans-excision-splicing 
riboZyme comprising at least tWo recognition elements that 
are complementary to target sequence Within a substrate 
other than that complementary to native recognition ele 
ments, Wherein at least one of said recognition elements 
stabiliZes binding of the riboZyme to a trans-excision splic 
ing (TES) reaction intermediate product and Wherein the 
riboZyme catalyZes a speci?c excision of the target sequence 
and splices the 5' end of the substrate created by the excision 
to an 00G of the 3' end of the substrate created by the 
excision. 
Also provided are host cells transfected With the poly 
nucleotide molecule. 
In yet another aspect of the invention there is provided a 
method for in vitro trans-splicing-excison of a target 
sequence, comprising the steps of: 
(1) providing the riboZyme of the invention in a trans 
splicing reaction mixture; 
(2) providing a substrate comprising the target sequence 
to the reaction mixture; and 
(3) catalyZing the trans-splicing-excision of the target 
sequence. 
In another aspect of the invention there is provided a 
method for deleting an undesired genetic sequence from a 
host cell in vivo, said method comprising: 
(1) providing the riboZyme of the invention to the host 
cell, said riboZyme possessing catalytic activity against a 
target RNA sequence present in said host cell, Wherein the 
riboZyme catalyZes a speci?c excision of the target RNA 
sequence and splices the 5' end of the substrate created by 
the excision to an 00G of the 3' end of the substrate created 
by the excision. 
The folloWing de?nitions are used herein. 
RiboZyme: An RNA molecule that inherently possesses 
catalytic activity. 
Trans-splice: A form of genetic manipulation Whereby a 
nucleic acid sequence of a ?rst polynucleotide is colin 
early linked to or inserted colinearly into the sequence of 
a second polynucleotide, in a manner that retains the 3'-5' 
phosphodiester linkage betWeen such polynucleotides. By 
US 7,211,661 B2 
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“directed” trans-splicing or “substrate-speci?c” trans 
splicing is meant a trans-splicing reaction that requires a 
speci?c specie of RNA as a substrate for the trans-splicing 
reaction (that is, a speci?c specie of RNA in Which to 
splice the transposed sequence). Directed trans-splicing 
may target more than one RNA specie if the riboZyme is 
designed to be directed against a target sequence present 
in a related set of RNAs. 
Target sequence: Anucleic acid molecule, e.g., RNA, that is 
a substrate for the catalytic activity of a riboZyme of the 
invention. 
Expression Cassette: A genetic sequence that provides 
sequences necessary for the expression of a riboZyme of 
the invention. 
Stably: By “stably” inserting a sequence into a genome is 
intended insertion in a manner that results in inheritance 
of such sequence in copies of such genome. 
Operable linkage: An “operable linkage” is a linkage in 
Which a sequence is connected to another sequence (or 
sequences) in such a Way as to be capable of altering the 
functioning of the sequence (or sequences). For example, 
by operably linking a riboZyme encoding sequence to a 
promoter, expression of the riboZyme encoding sequence 
is placed under the in?uence or control of that promoter. 
TWo nucleic acid sequences, such as a riboZyme encoding 
sequence and a promoter region sequence at the 5' end of 
the encoding sequence, are said to be operably linked if 
induction of promoter function results in the transcription 
of the riboZyme encoding sequence and if the nature of the 
linkage betWeen the tWo sequences does not (1) result in 
the introduction of a frame-shift mutation, (2) interfere 
With the ability of the expression regulatory sequences to 
direct the expression of the riboZyme. Thus, a promoter 
region Would be operably linked to a nucleic acid 
sequence if the promoter Were capable of e?fecting the 
synthesis of that nucleic acid sequence. 
Native target sequence/Non-native target sequence: Native 
target sequence of a riboZyme is that polynucleotide 
sequence Which is recogniZed, bound and reacted by 
Wild-type (native) riboZymes. Non-native target sequence 
is sequence Within a substrate that is not bound by Wild 
type riboZyme and consequently native riboZyme does not 
react With non-native target sequence. Non-native target 
sequence can occur as a result of mutation, for example. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1. The Group I Intron Self-Splicing (1a: left) and 
Trans-Excision-Splicing Reactions (lb: right). The catalytic 
RNAs are represented by gray lines, the 5' and 3' exons and 
mimics are black lines, and the bridge (excised region) is a 
dotted line. The circle in the 5' exon represents a uridine and 
the circle in the 3' exon represents a guanosine. The intron 
inherently contains all the required activities for the trans 
excision-splicing reaction. RE1, RE2, and RE3 are three 
recognition elements that the catalytic RNAs may use to 
base pair With their substrates (RE1 is also referred to as the 
IGS, or Internal Guide Sequence.). It is likely that RE2 
and/or RE3 do not bind the substrate until after the ?rst 
reaction step. In addition, at least With the rP-8/4x riboZyme 
used herein, the guanosine cofactor is not required for 
initiation of the ?rst catalytic step. 
FIG. 2. The rP-8/4x and rP-8/4x-MD RiboZymes Base 
Pairing With Various Substrates. 2A) The R carinii 
riboZyme, rP-8/4x (uppercase lettering. SEQ ID NO:9), 
binding to the 36-mer substrate (loWercase lettering With a 
gray background, SEQ ID NO:10). In the trans-excision 
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splicing reaction, the bridging region (White lettering) is 
excised and the 5' and 3' regions of the substrate (black 
lettering) are subsequently spliced together. Note that P1, 
P9.0, and P10 are helices that result from the recognition 
elements RE1, RE2, and RE3 base pairing With the sub 
strate. The large bold arroWs indicate the sites of catalysis 
for the ?rst (left) and second (right) step of the trans 
excision-splicing reaction. The 5' uridine and 3' guanosine 
are circled. The riboZyme bases are numbered according to 
that for the R carinii intron (Testa, S. M., Haidaris, C. G., 
Gigliotti, E, & Turner, D. H. (1997) Biochemistry 36, 
15303*153 14.13, incorporated herein in its entirety). 2B). 
Simpli?ed diagrams of various substrates base pairing With 
various riboZymes. Only the recognition element sequences 
are shoWn for the riboZymes. The dashed line indicates a 
normal phosphodiester bond betWeen the adjoining 
sequences. i) The 12-mer substrate (SEQ ID NO:7) binding 
to rP-8/4x (SEQ ID NO:11). ii) The 10-mer substrate (SEQ 
ID NO:8) binding to rP-8/4x (SEQ ID NO:11). iii) The 
38-mer Myotonic Dystrophy substrate (SEQ ID NO: 12) 
binding to the rP8/4x-MD Myotonic Dystrophy riboZyme 
(SEQ ID NO:13). 
FIG. 3. The Trans-Excision-Splicing Reaction using the R 
carinii system. The Trans-Excision-Splicing (TES) Reaction 
Using the R carinii System. A) Polyacrylamide gel shoWing 
substrates and products of the TES reaction using 166 nM 
rP-8/4x riboZyme and 1.33 nM substrate at 7 mM MgCl2 
(36-mer) and 10 mM MgCl2 (10-mer and 12-mer) at 440 C. 
The reaction using the 36-mer substrate is diagrammed on 
the left (SEQ ID NO: 10. SEQ ID NO:14, and SEQ ID 
NO:15). The regions of the substrate that bind to the 
ribozyme’s recognition elements (labeled RE1 (SEQ ID 
NO:15). RE2, and RE3) are underlined. All reactions in the 
presence (+) and absence (—) of the rP-8/4x riboZyme Were 
subjected to the same incubation conditions. TES reactions 
Were conducted using a 36-mer substrate (to give a 16-mer 
product), a 12-mer substrate (9-mer product), and a 10-mer 
substrate (9-mer product). See FIG. 2 for the sequence of 
these substrates. The 6-mer lane shoWs a synthetic control 
for the 5' cleavage products, the 16-mer lane shoWs a 
synthetic control for the 16-mer TES product, and the “OH 
lane shoWs an alkaline digest of the 36-mer starting material. 
B). Graphs of TES reactions using the 36-mer substrate. All 
reactions Were run as above except for the changing vari 
able. The TES product is represented by ?lled circles and the 
5' cleavage product by open circles. C). Graphs of TES 
reactions using the 10-mer substrate. All reactions Were run 
as above except for the changing variable. The TES product 
is represented by ?lled triangles and the 5' cleavage product 
by open triangles. Each graph shoWs the average of tWo 
independent assays. 
FIG. 4. Sequencing of Trans-Excision-Splicing Products. 
For each system, a chemically synthesiZed version of the 
expected product Was sequenced and run adjacent to the 
isolated excision product. Left: the R carinii 16-mer product 
that results from treating the 36-mer substrate With the 
rP-8/4x riboZyme. Right: the Myotonic Dystrophy 10-mer 
product that results from treating the 38-mer substrate With 
the rP-8/4x-MD riboZyme. The dotted line represents the 
neWly created splice junction betWeen the 5' and 3' ends of 
the substrate. Nuclease T1 is speci?c for guanosine, U2 for 
adenosine, and CL-3 primarily for cytidine. The “OH lane 
shoWs an alkaline digest of the starting material, and the 
lanes labeled ‘Start’ shoW the starting material. 
FIG. 5. Competition TES Reactions. Polyacrylamide gel 
shoWing substrates and products of TES reactions using 166 
nM rP-8/4x, 7 mM MgCl2, and 440 C. ‘Radiolabeled sub 
US 7,211,661 B2 
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strate’ refers to the length of the radiolabeled substrate at 
1.33 nM ?nal concentration and ‘cold substrate’ refers to the 
length of the non-radiolabeled substrate. The ?nal concen 
trations of the cold substrates are 1.33 nM for the 36-mer, 
and 66.5 nM (50><) or 665 nM (500><) for the 7-mer, Which 
is r(GUGCUCU) (SEQ ID NO:16). The tWo substrates for 
each reaction Were added simultaneously. Lanes designated 
in the ?rst box are length controls, the second box shoWs the 
5' exon competition assay, the third box shoWs an alkaline 
digest of the 36-mer starting material, and the fourth box 
shoWs the 3' exon competition assay. 
FIG. 6. The TES Reaction Using the DMPK Model 
System. A) Polyacrylamide gel shoWing substrates and 
products of the TES reaction using 166 nM rP-8/4x-MD 
riboZyme, 1.33 nM substrate, 13 mM MgCl2, and 440 C. The 
reaction using the 38-mer DMPK mimic is diagrammed on 
the left (SEQ ID NO: 12. SEQ ID NO:17 and SEQ ID 
NO:18). The regions of the substrate that bind to the 
riboZyme’s recognition elements are labeled RE1 (SEQ ID 
NO: 18), RE2, and RE3. All reactions in the presence (+) and 
absence (—) of the rP-8/4x-MD riboZyme Were subjected to 
the same incubation conditions. TES reactions Were con 
ducted using the 38-mer substrate (to give a 10-mer prod 
uct). The 6-mer lane shoWs a synthetic control for the 5' 
cleavage products, the 10-mer lane shoWs a synthetic control 
for the 10-mer TES product, and the ‘OH lane shoWs an 
alkaline digest of the 38-mer starting material. The lanes 
labeled 36 are TES reactions using the rP-8/4x-MD 
riboZyme With the 36-mer R carinii substrate (at 13 mM 
MgCl2), and the lane labeled 38 (lane 0) is a reaction using 
the rP-8/4x riboZyme With the 38-mer DMPK mimic (at 7 
mM MgCl2). In these cases, no reaction occurs. B). Graphs 
of TES reactions using the 38-mer substrate and rP-8/4x 
MD. All reactions Were run as above except for the changing 
variable. The TES product is represented by ?lled squares 
and the 5' cleavage product by open squares. 
FIG. 7. TES reactions using tWo different Telrahymena 
riboZymes. FIG. 7A is a polyacrylamide gel shoWing sub 
strates, intermediates, and products of the TES reaction. The 
reaction Was carried out for 90 minutes using 166 nM 
riboZyme and 1.33 nM radiolabeled 13-mer substrate at 
either 0 mM or 10 mM MgCl2 at 44 degrees C, either in the 
presence (+) or absence (—) of 330 nM GMP. FIG. B is a 
diagram of the TES reaction (SEQ ID NO:19 and SEQ ID 
NO:20). The excised G of SEQ ID NO:19 is in bold 
lettering. FIG. 7C shoWs tWo graphs of TES reactions using 
the 13-mer substrate and the A-L-21 Sca riboZyme (Telrahy 
menu). The TES product is represented by the ?lled circles 
and the 5' intermediate (CUCUCU) (SEQ ID NO:21) is 
represented by open circles. All reactions Were run as above 
except for the changing variable. Each curve represents the 
average of tWo independent assays. Standard deviation for 
all points Was less than 10%. For clarity the graphs use 
different scales. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The inherent binding and catalytic activity of group I 
intron-derived riboZymes can be exploited to catalyZe the 
trans-excision-splicing reaction. FIG. 1a shoWs a simple 
diagram of a typical group I intron-catalyZed self-splicing 
reaction. There are three base pairing contacts that the intron 
uses to hold and position its 5' and 3' exons for subsequent 
catalysis. We have termed these the riboZyme recognition 
elements, or RE1, RE2, and RE3. Physically removing the 
intramolecular exons from the intron creates a riboZyme that 
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has the ability to bind and catalyZe reactions using exog 
enous substrates that contain 5' and 3' exon sequences (Zaug, 
A. J. & Cech, T. R. (1986) Science 231, 4704475.). Ifthe 5' 
and 3' exon sequences are connected With a bridging 
sequence and recognition elements are maintained, this 
riboZyme can excise the bridging sequence and splice the 5' 
and 3' ends of the substrate together. A simple diagram of 
this trans-excision-splicing reaction is shoWn in FIG. 1b. 
This reaction Was tested using a riboZyme, rP-8/ 4x, from the 
opportunistic pathogen Pneumocyslis carinii. In FIG. 2A it 
is shoWn that this riboZyme catalyZes the trans-excision 
splicing reaction using a synthetic substrate Which is 
complementary to the native recognition elements of the 
rP-8/4x riboZyme. Moreover, as little as a single nucleotide 
can be excised. 
In order for this reaction to be useful, hoWever, the 
riboZyme recognition elements have to be mutable, such that 
the riboZyme can be targeted to bind With and react on 
non-native sequences. Using a group I intron-derived 
riboZyme from Telrahymena lhermophila, the sequence of 
RE1 (also referred to as the IGS, or Internal Guide 
Sequence) Was mutated and the resultant riboZyme then 
bound to a neW, complementary substrate (Murphy, F. L. & 
Cech, T. R. (1989) Proc. Natl. Acad. Sci. USA. 86, 
921849222; Been, M. D. & Cech, T. R. (1986) Cell 47, 
2074216; Zaug, A. 1., Been, M. D., & Cech, T. R. (1986) 
Nature 324, 4294433). This property has been exploited for, 
among other purposes, designing trans-splicing riboZymes 
that can replace the 3' end of mutant transcripts With 
corrected versions (Sullenger, B. A. & Cech, T. R. (1994) 
Nature 371, 61946; Lan, N., HoWrey, R. R, Lee, S. W., 
Smith, C. A., & Sullenger, B. A. (1998) Science 280, 
159341596). 
Trans-excision-splicing riboZymes are ideal for treating 
genetic diseases for Which the causative affects may be 
ameliorated by the excision of an internal RNA segment out 
of a larger RNA, including triplet-expansion diseases such 
as Huntington’s disease, Fragile X, and Myotonic Dystrophy 
(BoWater, R. P. & Wells, R. D. (2001) Prog. Nucleic Acid 
Res. Mol. Biol. 66, 1594202). Patients affected with these 
diseases have an RNA that is present in normal individuals, 
except that embedded Within it is an abnormally high 
number of tandem repeat sequences. For Myotonic Dystro 
phy, the expansion is in the 3' llnIranslated Region [3' UTR] 
of a serine-threonine protein kinase gene [the DMPK gene], 
Whose expression induces the expression of skeletal muscle 
speci?c genes. The disease state of Myotonic Dystrophy, 
Which is the most common form of adult onset Muscular 
Dystrophy, typically has much more than 35 CUG repeats, 
While una?fected individuals typically have less than 15 
repeats. The greater the number of repeats, the more severe 
the affects of the disease. Moreover, strong experimental 
evidence indicates the disease stems directly from the RNA 
repeats, and not to any a?fected coding potential of the parent 
DNA. In fact, the Myotonic Dystrophy triplet-expansion and 
recently discovered quadruplet-expansion diseases have the 
repeat sequences Within non-coding regions, so their effects 
are not due to the synthesis of mutant proteins. A neW class 
of riboZymes that can speci?cally excise these expanded 
RNA repeats from the transcripts could aid in the develop 
ment of much needed therapeutics against these types of 
diseases. 
The rP-8/4x riboZyme Was re-engineered to test the poten 
tial to alter the sequence speci?city of trans-excision-splic 
ing riboZymes to bind and excise the triplet expansion region 
from a Myotonic Dystrophy DMPK small model system in 
vitro. The resultant riboZyme excises the triplet expansion 
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region, and in a sequence speci?c manner. That trans 
excision-splicing ribozymes can be re-engineered to target 
and act upon predetermined sequences demonstrates a gen 
eral usefulness for these ribozymes as biochemical tools and 
therapeutics . 
R carinii group I intron ribozyme catalyzes the trans 
excision-splicing reaction. 
A ribozyme derived from a R carinii group I intron 
catalyzes a previously unreported excision-splicing reaction 
on an exogenous substrate. This trans-excision-splicing 
reaction takes advantage of the catalytic abilities of this 
ribozyme. First, rapid and ef?cient sequence-speci?c cleav 
age of a designated substrate occurs in a guanosine inde 
pendent fashion, as previously reported (Testa, S. M., Hai 
daris, C. G., Gigliotti, F., & Turner, D. H. (1997) 
Biochemistry 36, 15303*15314.). Second, the resultant 5' 
cleavage product can splice to a sequence that binds the 3' 
end of the ribozyme (Inoue, T., Sullivan, F. X., & Cech, T. 
R. (1985) Cell 43, 431*437) (FIG. 1B). These activities Were 
exploited by designing a synthetic substrate that contains 
Within it the sequences required for each catalytic event, 
separated by an internal bridging sequence (FIG. 2A). As 
seen in FIG. 3, the engineered ribozyme catalyzes the 
speci?c excision of the bridge sequence and splices the 5' 
and 3' ends of the substrate back together. Even though there 
are 18 other uridines that could be sites of 5' cleavage and 
4 other guanines that could be sites of 3' splicing, only one 
trans-excision-splicing product is generated. Apparently, the 
ribozyme recognition elements that de?ne the individual 
catalytic steps are sequence speci?c. 
That the ribozyme can catalyze this reaction is surprising 
in that the relatively long bridging region could be expected 
to sterically hinder the binding of the substrate to the 
catalytic core of the ribozyme or hinder the required con 
formational rearrangement betWeen the tWo catalytic steps 
(Cech, T. R., Herschlag, D., Piccirilli, J. A., & Pyle, A. M. 
(1992) J. Biol. Chem. 267, l7479il7482; and 39. Jaeger, L., 
Michel, F. & Westhof, E. (1996) in Catalytic RNA, eds. 
Eckstein, F. & Lilley, D. (Heidelberg, Germany), Vol. 10, pp. 
1*17). Perhaps this accounts for over 50% of the substrate 
only undergoing the ?rst catalytic step (see FIG. 3). In 
addition, like other ribozymes, the P. carinii ribozyme binds 
its 5' exon sequences orders of magnitude tighter than its 3' 
exon sequences, Which alloWs time for 3' end dissociation 
prior to the second catalytic step. Nevertheless, a signi?cant 
amount of trans-excision-splicing product is generated. 
Another consideration is that the 5' exon of one substrate 
could ligate to the 3' exon of another substrate. Since 
spontaneous 3' splice site hydrolysis is essentially non 
existent and only an insigni?cant amount of 5' exon-bridge 
26-mer product (Which Would be a side reaction of this 
catalytic event) is produced, it is unlikely that this mecha 
nism occurs to a signi?cant extent. 
The R carinii ribozyme can excise as little as one nucle 
otide. The R carinii ribozyme excises as little as a single 
nucleotide, and in a sequence-speci?c manner. Apparently, 
there is no loWer limit to the size of the region being excised. 
That the same approximate yield is obtained regardless of 
Whether the 12-mer (39%) and 10-mer (36%) substrate is 
used suggests that the role of forming the P90 helix is not 
large in this case, as the 10-mer lacks the ability to form the 
P90 helix. Therefore, the RE2 interaction, although perhaps 
bene?cial, is not required to establish a sequence speci?c 
interaction. In addition, the 12-mer and 10-mer substrates 
lead to approximately 50% more product as compared With 
the 36-mer substrate. There are many possible explanations 
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for this, including the longer bridge of the 36-mer substrate 
partially interfering With the substrate’s ability to bind the 
recognition elements. 
The sequence speci?city of the R carinii ribozyme can be 
altered. Altering the recognition elements of the R carinii 
ribozyme changes the sequence speci?city of the trans 
excision-splicing reaction. While it Was knoWn that RE1 
could be modi?ed in reactions mimicking the ?rst step of the 
self-splicing reaction, it Was previously not knoWn that all 
three elements are mutable. That these recognition elements 
completely specify binding and reactivity indicates that they 
are the primary determinants of speci?city betWeen the 
ribozyme and its substrate. In addition, bridging regions of 
different sequences and lengths (1, 3, 20, and 28 nucleotides) 
have been excised, indicating that the 3' G in the bridging 
region might be the only potential sequence requirement for 
the excised segment. Structure might even be tolerated 
Within the excised region, as the someWhat structured CUG 
repeat Within the Myotonic Dystrophy substrate doesn’t 
prohibit the reaction. In addition, each ribozyme only acts 
upon its designated target, even though the RBIs in both 
ribozymes are 50% identical, giving a further indication of 
the high level of sequence speci?city of this reaction. 
Although the MgCl2 concentration required for maximum 
activity is di?cerent for the tWo ribozymes (7 and 13 mM), 
they both are active throughout the same general MgCl2 
concentration range (data not shoWn), Which is beloW that 
required (15 mM) for maximum activity for the R carinii 
group I intron self-splicing reaction in vitro. 
The ability to catalyze TES reactions is inherent to Group 
I introns. To determine Whether other ribozymes can cata 
lyze TES reaction, a Tetrahymena icontaining L-21 ScaI 
plasmid Was linerarized With ScaI, run-01f transcriptions 
Were performed, and the ribozyme Was puri?ed as described 
by Testa et al. (Biochemistry, (1997) 36:15303*15314). TES 
reactions Were run in a variety of standard buffers and 
conditions routinely used for ribozyme reactions. The reac 
tions Were also run in the presence and absence of the PG 
cofactor. In all cases, the ?rst step of the reaction Was the 
only reaction step that Was detected. 
The lack of a full-length, second-step reaction product 
suggests that the second step may be inef?cient or problem 
atic With this ribozyme. Our previous studies of the R carinii 
ribozyme had demonstrated that 3' intermediate disassocia 
tion results in signi?cantly reduced second-step yields. 
Therefore, the Telrahymena ribozyme Was modi?ed to con 
tain an RE3 region in order to stabilize binding of the 
ribozyme to the ’3 exon reaction intermediate. The results 
are shoWn in FIG. 6. The reaction using the stabilized 
ribozyme generates a product band of the expected size (a 
12-mer product from a 13-mer substrate). The product band 
Was excised from the band and sequenced, and shoWn to be 
the expected TES product. These results demonstrate that 
the the ability to catalyze TES reactions is a general property 
inherent to group I introns. 
Comparison With the Trans-Splicing Reaction. The trans 
excision-splicing reaction of the invention is fundamentally 
different from the trans-splicing reaction previously reported 
(Sullenger, B. A. & Cech, T. R. (1994) Nature 371, 
619*622.), Whereby a ribozyme covalently attached to a 
normal RNA sequence binds to a mutant RNA transcript, 
cleaves the mutant transcript, and replaces the 3' end of the 
mutant transcript With the normal ‘corrected’ version. While 
trans-splicing can correct mutant RNA, it is single-tumover, 
it exploits only the RBI molecular interaction, and the 
ribozyme must be covalently attached to the neW, corrected 
transcript. In contrast, the trans-excision-splicing reaction is 
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potentially multiple turnover; it exploits the RBI, RE2, 
and/ or RE3 molecular interactions; and it excises an internal 
segment from Within a larger RNA. Nevertheless, these tWo 
complementary reactions share many similarities and so the 
Wealth of knowledge already reported for the trans-splicing 
reaction is applicable to the trans-excision-splicing reaction. 
Implications for Myotonic Dystrophy. The rP-8/4x 
riboZyme can be redesigned to speci?cally excise the entire 
triplet expansion region of a mimic of the Myotonic Dys 
trophy transcript, implicating such riboZymes as neW types 
of potential Muscular Dystrophy therapeutics. As a practical 
matter, cutting out this entire region may or may not restore 
proper function to the transcript, as normal individuals 
typically have at least 5 repeats. Similar multiple turnover 
riboZymes, hoWever, can be designed to target the repeats 
themselves to successively reduce expansion lengths. 
General Therapeutic Implications. Unfortunately, nature 
has a?‘orded a huge number of RNA-mediated mutations 
that predispose individuals to disease. NeW therapeutic 
strategies to combat these diseases are needed. That the 
recognition elements of the rP-8/4x riboZyme can be modi 
?ed and the siZe and sequence of the excised region do not 
appear to have limitations suggest that trans-excision-splic 
ing riboZymes may be generally useful as therapeutics 
against many such diseases. For example, excising speci?c 
sequences could remove premature stop codons, restore 
altered reading frames, or remove insertion mutations that 
a?fect transcription and translation regulation. 
Trans-excision-splicing riboZymes are thought to have 
tWo sequence preferences. The ?rst is a uridine at the 5' 
cleavage site (although a cytidine might also Work) and the 
second is a guanosine at the 3' splice site (FIG. 2A). 
Therefore, there are three simple targeting strategies to 
consider. First, a riboZyme can be designed that targets a 
uridine 5' to any particular mutation and a guanosine 3' to 
this mutation, as is the case in the Myotonic Dystrophy 
model system described here. It should be noted that if more 
than an insertion mutation is excised the neW transcript 
might not function normally. Second, a mutation that results 
in a neW guanosine can be targeted as the 3' splice site. The 
above strategies Will also target normal transcripts for at 
least the ?rst step of the reaction, so these strategies should 
be designed With care. Third, a mutation that results in a neW 
uridine can be targeted as the 5' cleavage site. This resultant 
riboZyme Would not attack the normal transcript, but Would 
perform both steps on the mutant transcript. Since point 
mutations that result in premature termination codons often 
involve a neW uridine (all termination codons begin With 
uridine), hundreds of distinct mutations could be speci?cally 
targeted. Therefore, many options for targeting are possible, 
Which expands the potential usefulness of these riboZymes. 
The general strategy of targeting mutations at the RNAlevel, 
hoWever, should be considered a potential treatment rather 
than a potential cure, as mutant RNA transcripts Will con 
tinue to be produced. 
As shoWn herein, group I intron-derived riboZymes 
obtained from different organisms can catalyZe this neW 
trans-excision-splicing reaction. In addition, the sequence of 
the riboZyme can be easily manipulated such that it targets 
and acts upon desired substrates, including those of medical 
importance. The reactions themselves appear highly 
sequence speci?c and as little as a single nucleotide can be 
excised. The applicability of trans-excision-splicing 
riboZymes to treat disease has been demonstrated by design 
ing a riboZyme that speci?cally removes the triplet expan 
sion region that is involved in a common form of Muscular 
Dystrophy in a small model system in vitro. Therefore, 
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trans-excision-splicing riboZymes are a neW class of 
riboZymes that permits potential biochemical and therapeu 
tic strategies not before possible. 
The riboZymes of the invention can be introduced into and 
expressed in a host cell. Transcription of the riboZyme of the 
invention in a host cell occurs after introduction of the 
riboZyme gene into the host cell. If the stable retention of the 
riboZyme by the host cell is not desired, the riboZyme may 
be chemically or enZymatically synthesized and provided to 
the host cell by mechanical methods, such as microinjection, 
liposome-mediated transfection, electroporation, calcium 
phosphate precipitation, or the like. Alternatively, When 
stable retention of the gene encoding the riboZyme is 
desired, such retention may be achieved by stably inserting 
at least one DNA copy of the riboZyme into the host’s 
chromosome, or by providing a DNA copy of the riboZyme 
on a plasmid that is stably retained by the host cell. Pref 
erably the riboZyme of the invention is inserted into the 
host’s chromosome as part of an expression cassette, Which 
provides transcriptional regulatory elements that control the 
transcription of the riboZyme in the host cell. Such elements 
may include, but not necessarily be limited to, a promoter 
element, an enhancer or UAS element, and a transcriptional 
terminator signal. Polyadenylation is not necessary as the 
riboZyme is not translated. 
Expression of a riboZyme Whose coding sequence has 
been stably inserted into a host’s chromosome is controlled 
by the promoter sequence that is operably linked to the 
riboZyme coding sequences. The promoter that directs 
expression of the riboZyme may be any promoter functional 
in the host cell, prokaryotic promoters being desired in 
prokaryotic cells and eukaryotic promoters in eukaryotic 
cells. A promoter is composed of discrete modules that direct 
the transcriptional activation and/or repression of the pro 
moter in the host cell. Such modules may be mixed and 
matched in the riboZyme’s promoter so as to provide for the 
proper expression of the riboZyme in the host. A eukaryotic 
promoter may be any promoter functional in eukaryotic 
cells, and especially may be any of an RNA polymerase I, II 
or III speci?city. If it is desired to express the riboZyme in 
a Wide variety of eukaryotic host cells, a promoter functional 
in most eukaryotic host cells should be selected, such as a 
rRNA or a tRNA promoter, or the promoter for a Widely 
expressed mRNA such as the promoter for an actin gene, or 
a glycolytic gene. If it is desired to express the riboZyme 
only in a certain cell or tissue type, a cell-speci?c (or 
tissue-speci?c) promoter element that is functional only in 
that cell or tissue type should be selected. 
The trans-splicing reaction is chemically the same 
Whether it is performed in vitro or in vivo. HoWever, in vivo, 
the presence of the target and the riboZyme Will suf?ce to 
result in trans-splicing, since cofactors are usually already 
present in the host cell. 
It has been previously reported that, at high MgCl2 
(l0*l00 mM) and temperature (550 C. to 650 C.), Telrahy 
menu group I intron riboZymes that lack both of the exons 
and the IGS can catalyZe a guanosine cofactor-mediated 
TES-like reaction upon binding pseudoknot structured sub 
strates, Which creates the in trans equivalent of the P1 and 
P10 helices (P9.0 helix formation Was not required). The 
riboZymes target and bind these pseudoknot structures 
entirely through tertiary interactions. In contrast, the 
riboZymes used in the present invention contain at least tWo 
modi?able REs. In a preferred embodiment, the riboZyme 
conatins modi?ed RBI and RE3. Which alloWs the riboZyme 
to target designated substrates at the level of simple base 
pairing. Furthermore, the TES reactions using the R carinii 
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and Telrahymena riboZymes do not require a guanosine 
cofactor, and optimally occur at a lower MgCl2 concentra 
tion (7413 mM) and temperature (440 C.). 
Sullenger and Cech ((1994) Nature 371, 6194622.) pre 
viously reported that Telrahymena group I intron riboZymes 
that lack a 5' exon, but contain an endogenous non-native 3' 
exon, catalyze the covalent attachment of the endogenous 3' 
exon to mutant transcripts in such a Way as to replace the 3' 
end of mutant transcripts With normal ‘corrected’ versions. 
While trans-splicing can repair RNA, it exploits only the 
RE1 molecular interaction, the riboZymes must be 
covalently attached to the repaired half of the transcript, it is 
single-turnover, and repairing mutations distant from the 3' 
end of long transcripts could be problematic. In contrast, the 
TES reaction exploits multiple molecular interactions (RE1, 
RE3, and perhaps RE2), TES riboZymes excise an internal 
segment from Within RNA substrates, the reaction is poten 
tially multiple turnover, and the position of the mutations 
Within the transcript is not a limiting factor. Moreover, that 
under the conditions used in this report, little (if any) 
turnover Was observed. 
EXAMPLE 1 
0ligonucleotide synthesis and preparation. DNA oligo 
nucleotide primers Were purchased from Integrated DNA 
Technologies (Coralville, IoWa), and Were used Without 
further puri?cation. RNA oligonucleotides Were purchased 
from Dharmacon Research Inc. (Boulder, Colo.) and depro 
tected folloWing the manufacturer’s protocol. The oligori 
bonucleotides Were 5' end radiolabeled and puri?ed via gel 
electrophoresis as previously described (Testa, S. M., Hai 
daris, C. G., Gigliotti, E, & Turner, D. H. (1997) Biochem 
islry 36, 15303415314). The RNA products Were extracted 
from the gel slice by stirring for one hour With a sterile 
stir-bar in 1.5 mL elution buffer containing 10 mM Tris (pH 
7.4), 250 mM NaCl, and 1 mM EDTA. Gel particulate Was 
removed via centrifugation, and the solution Was evaporated 
to a ?nal oligoribonucleotide concentration of approxi 
mately 8 nM. 
Plasmid construction and synthesis. The R carinii 
riboZyme plasmid precursor, P-8/4x, Was generated as pre 
viously described (Testa, S. M., Haidaris, C. G., Gigliotti, E, 
& Turner, D. H. (1997) Biochemistry 36, 153034153 14). 
The Myotonic Dystrophy-speci?c riboZyme plasmid precur 
sor, P-8/4x-MD, Was derived from the P-8!4x plasmid by 
site-directed mutagenesis. Brie?y, three successive rounds 
of mutagenesis Were performed to modify each of the three 
recognition elements using the folloWing pairs of mutagenic 
primers (underlined bases represent altered recognition ele 
ments as compared to P-8/4x)1 5' CACGCCGCTTTC 
GGGAACCTCTATAGTGAGTCG3v (SEQ ID N011) and 5' 
CGACTCACTATAGAGGTTCCCGAAAGCGGCGTG3 ' 
(SEQ ID N012) for RE1 formation, 5' GGTATAGTCT 
mCCTCTTTCGAAAG3v (SEQ ID N013) and 5' CTTTC 
GAAAGAGGQAGACTATACC3v for RE2 (SEQ ID 
N014) formation, and then 5' CGACTCACTATA 
@GTTCCCGAAAGCGGC3v (SEQ ID N015) and 5' 
GCCGCTTTCGGGAACACCTATAGTGAGTCG3v (SEQ 
ID N016) for RE3 formation. 
Each set of primers (15 pmol each primer) Was used in an 
ampli?cation reaction comprising 25 ng parental plasmid, 
2.5 units Pfu DNA polymerase (Stratagene; La Jolla, Calif.), 
and 0.5 uM dNTPs in a buffer comprising 10 mM KCl, 10 
mM (NH4)2S04, 20 mM Tris-HCl (pH 8.8), 2 mM MgS04, 
0.1% Triton X-100, and 0.1 mg/mL BSA (?nal volume 50 
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uL). After an initial denaturation for 30 seconds at 95° C., 
the mixture Was subjected to 15 cycles of 95° C. for 30 
seconds, 500 C. for tWo minutes, and 68° C. for six minutes. 
Parental plasmid Was then digested With 20 units Dpn I 
(Gibco BRL; Rockville, Md.) in 5.7 pL of the manufactur 
er’s supplied buffer for 2 hours at 37° C. 3 pL of this mixture 
Was then used to transform E. coli DHSO. competent cells 
(Gibco BRL). The vectors Were puri?ed using a QIAprep 
Spin Miniprep Kit (QIAGEN; Valencia, Calif.). The result 
ant ?nal plasmid, P-8/4x-MD, Was sequenced for con?rma 
tion (ACGT, Inc; Northbrook, Ill.). The plasmids Were 
lineariZed With Xba I, phenol/chloroform extracted, and 
ethanol precipitated in preparation for run-olf transcription. 
Transcription. Both rP-8/4x and rP-8/4x-MD Were tran 
scribed from their appropriate plasmid precursors essentially 
as previously described for rP-8/4x (Testa, S. M., Haidaris, 
C. G., Gigliotti, E, & Turner, D. H. (1997) Biochemistry 36, 
15303415314). A typical transcription reaction (40 pL) 
contained 1 pg lineariZed plasmid, 40 mM Tris-HCl (pH 
7.4), 5 mM dithiothreitol, 5 mM spermidine, 5 mM MgCl2, 
1.5 mM each NTP, 1.25 mg/mL BSA, and 4 pL of T7 RNA 
polymerase (100 units/uL) and Was incubated for tWo hours 
at 37° C. The resultant RNA Was puri?ed using QIAGEN-tip 
100 anion-exchange columns. First, each column Was equili 
brated With 4.0 mL of Bulfer I (750 mM NaCl, 50 mM 
MOPS (pH 7.0), 15% ethanol, and 0.15% Triton X-100). 
Second, the transcription reactions Were loaded onto the 
column and the column Was Washed With 7.0 mL of Buffer 
I. Third, the transcripts Were eluted using 4.0 mL of Buffer 
II (1.0 M NaCl, 50 mM MOPS (pH 7.0), and 15% ethanol). 
Following an isopropanol and then an ethanol precipitation, 
the samples Were dissolved in Water and quanti?ed using a 
Beckman UV-VIS DU-650 spectrophotometer. 
Trans-excision-splicing reactions. Reactions Were con 
ducted in HxMg buffer consisting of 50 mM Hepes (25 mM 
Na’’), 135 mM KCl, and ><mM MgCl2 (listed in the ?gures) 
at pH 7.5. The trans-excision-splicing reactions Were opti 
miZed for the rP-8/4x and rP-8/4x-MD riboZymes over a 
MgCl2 concentration range of0 to 50 mM at 30° C., 37° C., 
and 44° C. Maximum product formation occurred at 44° C. 
for both riboZymes, 7 mM MgCl2 for rP-8/4x, and 13 mM 
MgCl2 for rP-8/4x-MD, although a signi?cant amount of 
each product Was obtained at 37° C. at both 7 and 13 mM 
MgCl2 for each riboZyme (data not shoWn). Prior to each 
reaction, 1.0 pmol of riboZyme in 5.0 pL of the appropriate 
buffer Was preannealed at 60° C. for ?ve minutes and then 
alloWed to sloW-cool to the appropriate temperature. Reac 
tions using the rP-8/4x riboZyme Were initiated by adding 
1.0 pL of 8 nM radiolabeled 36-mer, 12-mer, or 10-mer R 
carini-speci?c substrates or the 38-mer Myotonic Dystrophy 
substrate. Reactions using the rP-8/4x-MD riboZyme Were 
initiated by adding 1.0 pL of 8 nM radiolabeled 38-mer 
Myotonic Dystrophy-speci?c substrate or the 36-mer R 
carinii substrate. The substrate sequences and hoW they base 
pair With the riboZymes are shoWn in FIG. 2. In each case the 
substrates Were preincubated in the appropriate buffer (listed 
in the ?gures). After one hour, the reactions Were terminated 
by adding an equal volume of stop buffer (10 M urea, 3 mM 
EDTA, and 0.1><TBE). The products and reactants Were 
denatured for one minute at 90° C. and then separated on a 
12% acrylamide/8 M urea gel. The gel Was transferred to 
chromatography paper (Whatman 3MM CHR) and dried 
under vacuum. The bands Were visualiZed and quanti?ed on 
a Molecular Dynamics Storm 860 Phosphorimager. 
The observed rate constant, kobs, for the ?rst (5' cleavage) 
and second (exon ligation) step of each reaction Was quan 
ti?ed (Testa, S. M., GryaZnov, S. M. & Turner, D. H. (1998) 
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Biochemistry 37, 937949385; Mahadevan, M., Tsil?dis, C., 
Sabourin, L., Shutler, G., Amemiya, C., Jansen, G., Neville, 
C., Narang, M., Barcelo, 1., O’Hoy, K., et al (1992) Science 
255, 12534125). The ?rst step Was obtained from a plot of 
the percent intermediate plus percent product formed versus 
time, and the second step Was obtained from a plot of percent 
product formed versus time. These observed rate constants 
re?ect the rate of chemistry and any requisite conformation 
changes that occur. 
Sequencing the trans-excision-splicing products. Products 
obtained from the trans-excision-splicing reactions Were gel 
puri?ed and sequenced by partial nuclease digestion using 
T1 (Epicentre; Madison, Wis.), U2 (Research Unlimited; 
Wellington, NeW Zealand), and Cl-3 (Research Unlimited) 
RNA nucleases. T1 reactions used 1.0><10_4 units T1 in 200 
mM Tris-HCl (pH 7.5), Cl-3 reactions used 0.33 units Cl-3 
in 200 mM Tris-HCl (pH 7.5), and U2 reactions used 0.33 
units U2 in 200 mM Tris-HCl (pH 3.5). Sequencing reac 
tions utiliZed approximately 50 fmol of RNA and Were 
incubated for 10 minutes at 55° C. Immediately after adding 
an equal volume of stop buffer to each reaction, aliquots 
Were loaded on a 13.5% polyacrylamide/8 M urea gel. In 
parallel With the above reactions, We enZymatically 
sequenced chemically synthesiZed versions of the expected 
trans-excision-splicing products for comparison. 
To determine if the 3' product of the ?rst reaction step (5' 
cleavage) (FIG. 1B) is dissociating and then rebinding the 
same (or different) riboZyme before the second reaction step 
(exon ligation), TES reactions Were conducted for one hour 
in 7 mM MgCl2, 166 nM rP-8/4x riboZyme, 1.33 nM 
radiolabeled 36-mer substrate, and either 66.5 nM (50><) or 
665 nM (500><) 3' exon mimic competitor r(GUGCUCU) 
(SEQ ID NO:16). The values reported are the average of six 
independent assays. Likewise, to determine if the 5' product 
of the ?rst reaction step (5' cleavage) (FIG. 1B) is dissoci 
ating and then rebinding the riboZyme before the second step 
(exon ligation), TES reactions Were conducted for one hr in 
7 mM MgCl2, 166 nM rP-8/4x riboZyme, 1.33 nM 36-mer 
non-radiolabeled substrate, and 1.33 nM radiolabeled 5' 
exon mimic competitor r(AUGACU) (SEQ ID NO:15). In 
each case the competitors Were added simultaneously With 
the substrates. 
EXAMPLE 2 
The R carinii group I intron riboZyme catalyZes the 
trans-excision-splicing reaction. In order to test Whether a 
riboZyme derived from a group I intron, and speci?cally one 
from R carinii, catalyZes the trans-excision-splicing reac 
tion, a substrate Was designed that Would bind the rP-8/4x 
riboZyme’s native recognition element sequences (RE1, 
RE2, and RE3 in FIG. 1b). These substrate sequences Were 
connected With a bridge consisting of the ?rst four bases of 
the intron and 13 uridines (FIG. 2A). Uridines Where chosen 
because of their relatively poor ability to form self-structures 
and the number of uridines (13) Was chosen arbitrarily. 
Typical results at the optimiZed MgCl2 concentration (7 
mM) and the temperature (440 C.) are shoWn in FIG. 3A. 
The expected product band at 16 nucleotides in length 
Was obtained in a yield of 25%:5% (for 6 independently run 
assays). This band Was extracted from the gel matrix, 
repuri?ed, and subjected to enzymatic sequencing, along 
With a chemically synthesiZed version of the expected 
product. The sequence and banding patterns Were identical 
(FIG. 4), indicating that the expected trans-excision-splicing 
product Was generating. The reaction also produced a band 
at six nucleotides. This is a product of the ?rst step of the 
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tWo-step trans-excision-splicing reaction (5' cleavage), and 
indicates that a portion of the transcript undergoes only the 
?rst step of the reaction. Also produced is a small amount of 
riboZyme mediated 3' splice site hydrolysis product at 26 
nucleotides. Nonetheless, the rP-8/ 4x riboZyme contains the 
ability to bind a substrate in trans and catalyZe the excision 
splicing reaction. 
Apparently, a majority of the 36-mer substrate undergoes 
only the ?rst step of the reaction. The dependence of the TES 
reaction on MgCl2 concentration, time, and rP-8/4x concen 
tration is shoWn in FIG. 3B. The kobs for the ?rst and second 
step of the reaction are 1.69 and 0.05 min-1, respectively. 
The reaction is complete after 40 minutes and only requires 
20 nM riboZyme for maximal activity (With 1.33 nM sub 
strate). These results shoW that the rP-8/4x riboZyme, in the 
absence of a nucleotide cofactor, inherently contains the 
ability to bind a substrate in trans and catalyZe the TES 
reaction. 
Even though there are 18 other uridines that could be sites 
of 5' cleavage and four other guanosines that could be sites 
of 3' splicing for the 36-mer substrate, only the expected 
TES product is generated. Apparently, the riboZyme recog 
nition elements that de?ne the individual catalytic steps are 
sequence speci?c. That the riboZyme can catalyZe this 
reaction at all is surprising in that the relatively long 
bridging region could be expected to sterically hinder the 
binding of the substrate to the catalytic core of the riboZyme, 
or at least signi?cantly hinder the required conformational 
rearrangement betWeen the tWo catalytic steps. One or both 
of these might account for the majority (>50%) of the 
36-mer substrate only undergoing the ?rst catalytic step, in 
contrast to less than 10% only undergoing the ?rst step for 
the self-splicing reaction in vitro (15, 17). The lack of 
product breakdown seen in the time dependence studies, 
hoWever, indicates that the TES products themselves are not 
substrates for further reactions, although guanosine depen 
dent 5' cleavage or riboZyme-mediated hydrolysis of the 
products could be a factor in vivo. 
Previous studies utiliZing the rP-8/4x riboZyme (Testa, S. 
M., GryaZnov, S. M. & Turner, D. H. (1998) Biochemistry 
37, 937949385) shoW that the 5' exon mimic r(AUGACU) 
(SEQ ID NO:15) binds to the rP-8/4x riboZyme (Kd:5.2 nM 
at 37° C.) three orders of magnitude more tightly than the 3' 
exon mimic r(GUGCUCU) (SEQ ID NO:16) (Kdz20 uM at 
37° C.). Interestingly, maximum TES product formation 
occurs With as little as 20 nM riboZyme (at 44 ° C.), 
indicating that for ?nal product formation the 5' and 3' exon 
intermediates produced during the 5' cleavage step might not 
dissociate and then rebind the riboZyme before the exon 
ligation step. To test for 5' exon dissociation and rebinding 
betWeen the tWo steps, TES reactions Were conducted With 
166 nM rP-8/4x, 1.33 nM non-radiolableled 36-mer, and 
1.33 nM radiolabeled 5' exon, r(AUGACU) (SEQ ID 
NO:15). In this case, if the 5' exon intermediate dissociates 
from the riboZyme, the radiolabeled 5' exon is just as likely 
to then bind the riboZyme and form the 16-mer product as 
the non-radiolabeled 5' exon intermediate. As seen in FIG. 5, 
no radiolabeled TES products are observed, indicating the 5' 
exon intermediate does not dissociate from the riboZyme 
betWeen the tWo steps (for those 5' exon intermediates that 
undergo the complete reaction). 
LikeWise, to test for 3' exon intermediate dissociation and 
rebinding betWeen the tWo reaction steps, TES reactions 
Were conducted With 166 nM rP-8/ 4x, 1.33 nM radiolabeled 
36-mer, and a 50 (66.5 nM) or 500 (665 nM) fold excess of 
a non-radiolabeled 3' exon mimic competitor, 
r(GUGCUCU) (SEQ ID NO:16) Which Would form a 
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10-mer competition product. At equal molar concentrations 
if the 3' exon intermediate dissociates from the riboZyme, the 
7-mer competitor is 2.5 times more likely to bind the 
riboZyme and be a substrate in the second reaction step than 
the 30-mer 3' exon intermediate (data not shoWn). The 
results (FIG. 5) shoW that a 500-fold excess of cold com 
petitor over substrate does not signi?cantly reduce the 
amount of 16-mer product formed (19.4%:2.3% versus 
22.8%:3%, respectively). The small amount of 10-mer 
product that is observed at 500-fold excess competitor over 
substrate (but not 50-fold excess) is not actually competing 
With the TES reaction. In these cases, the riboZymes that 
have bound radiolabeled 5' exon regions, and for Which the 
3' exon region has dissociated, are binding and reacting With 
a small amount of the huge excess of 3' exon competitor. 
Therefore, the vast majority of substrates that undergo the 
complete TES reaction do not have 3' exon intermediate 
dissociation and rebinding occurring betWeen the tWo steps 
of the reaction. Apparently, substrates that undergo only the 
?rst reaction step do so because of nearly irreversible 5' or 
3' exon intermediate dissociation. It folloWs that since 
intermediates to the complete TES reaction do not dissociate 
from the riboZyme, the TES reaction is intramolecular With 
regard to substrate. 
EXAMPLE 3 
Excision of a single nucleotide using the R carinii. 
riboZyme. In order to determine if a loWer limit exists to the 
length of the excised region, We tested the TES reaction 
using the rP-8/4x riboZyme With tWo neW substrates. One 
substrate is a 12-mer, r(AUGACUGUGCUC) (SEQ ID 
NO:7), and Was designed to contain the minimum length 
bridging sequence that could utiliZe the 2 base pair RE2 
interaction (to form the P90 helix) and the 3' guanosine 
thought to be required for self-splicing (FIG. 2Bi). The other 
substrate is a 10-mer, r(AIKLACllGClLC) (SEQ ID NO:8), 
Which can not utiliZe the RE2 interaction, and from Which 
only one nucleotide Would be excised (FIG. 2Bii). The 
results (FIG. 3A) shoW that, under the optimal conditions of 
10 mM MgCl2 and 440 C., both the 12-mer and 10-mer 
reactions lead to the formation of the expected 9-mer 
products, as con?rmed by enZymatic sequencing (data not 
shoWn). The optimiZed reactions produce 72%:3.9% prod 
uct for the 12-mer substrate and 69.3%:4.4% product for the 
10-mer substrate (for 6 independently run assays). Thus, the 
rP-8/4x riboZyme can excise as little as a single nucleotide. 
The same approximate yield is obtained using the 12-mer 
and 10-mer substrates Which suggests that the role of 
forming the P90 helix is not large in this case. Therefore, the 
RE2 interaction, although perhaps bene?cial, is not required 
for sequence speci?c TES reactions. In addition, the 12-mer 
and 10-mer substrates lead to more than tWice the product as 
compared With the 36-mer substrate, implicating the longer 
bridging region (Which includes the four 5' bases of the 
intron) as being detrimental for this reaction. As the amount 
of substrate that undergoes at least the ?rst reaction step is 
similar for all of the different substrates, 3' exon intermediate 
dissociation for the 36-mer likely accounts for the difference 
in extent of ?nal product formation. The dependence of the 
10-mer substrate reaction on MgCl2 concentration, time, and 
rP-8/4x concentration is shoWn in FIG. 3C. The kobs for the 
?rst and second step of the reaction are 4.12 and 2.89 min-l, 
respectively. In contrast to that for the 36-mer, the reaction 
With the 10-mer substrate is more favorable at MgCl2 
concentrations greater than 7 mM, and the second reaction 
step occurs approximately 50-fold faster. The origin of this 
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effect is unknown, but could be due to the reduced steric 
hindrance of the smaller bridge on the required conforma 
tional rearrangement betWeen the tWo reaction steps. This 
could re?ect an increased af?nity or accessibility of the 3' 
guanosine of the bridge for the G-binding site of the 
riboZyme. Indeed, previous reports suggest that the ability of 
the G-binding site to bind this endogenous guanosine drives 
the second step of the reaction (Mahadevan, M., Tsil?dis, C., 
Sabourin, L., Shutler, G., Amemiya, C., Jansen, G., Neville, 
C., Narang, M., Barcelo, 1., O’Hoy, K., et al (1992) Science 
255, 125341255; Harley, H. G., Rundle, S. A., MacMillan, 
1. C., Myring, 1., Brook, 1. D., CroW, S., Reardon, W., 
Fenton, 1., Shaw, D. 1., & Harper, P. S. (1993) Am. J. Hum. 
Genet. 52, 116441174). 
EXAMPLE 4 
The sequence speci?city of the R carinii riboZyme can be 
altered. For the TES reaction to be useful, the recognition 
elements must be mutable in order to target predetermined 
sequences. Therefore, a truncated DMPK mimic model 
system Was developed (FIG. 2Biii) for analyZing the ability 
of a re-engineered riboZyme to excise the RNA triplet repeat 
region Whose expansion is the causative agent of the effects 
of the genetic disease, Myotonic Dystrophy. AriboZyme Was 
designed to target the uridine immediately upstream of the 
repeats. Because there are ?ve successive guanosines imme 
diately folloWing the repeats (Which could lead to a mixture 
of TES products), the ?rst guanosine doWnstream from the 
?ve successive guanosines Was targeted. The substrate 
bridge contained 5 CUG repeats, as this is the smallest 
number of repeats thought to form the hairpin structure 
similar to that seen With the expanded transcripts. Myotonic 
Dystrophy patients actually have greater than 15 CUG 
repeats. Nevertheless, the riboZyme targets the ?anking 
regions and Would be the same regardless of the number of 
triplet repeats. This riboZyme is referred to as the rP-8/4x 
MD riboZyme and this substrate the 38-mer DMPK mimic. 
The results at the optimum MgCl2 concentration (13 mM) 
and temperature (440 C.) are shoWn in FIG. 6A. A 10 
nucleotide product Was obtained, as expected, in a yield of 
61.1%:4.6% (for 6 independently run assays). Besides 
unreacted 6-mer generated from the ?rst step of the reaction, 
no other products are produced to any signi?cant amount, 
indicating a reasonably speci?c reaction. The 10-mer prod 
uct Was extracted from the gel and enZymatically sequenced, 
along With a chemically synthesiZed version of the expected 
product. The sequence and banding patterns obtained (FIG. 
4) shoW that the expected TES product is being generated. 
Apparently, the riboZyme can be modi?ed (at RE1, RE2, and 
RE3) to target non-native substrates. The dependence of this 
reaction on MgCl2 concentration, time, and rP-8/4x-MD 
concentration is shoWn in FIG. 6B. The kobs for the ?rst and 
second step of the reaction are 0.41 and 0.44 min-l, respec 
tively (note that these values are Within experimental error 
and the rate of the second step is likely limited by the rate 
of the ?rst step). Interestingly, the excision of this 28-mer 
bridge, Which could include a triplet repeat hairpin structure, 
is substantially more effective than the 36-mer rP-8/4x 
system, Which excises a 20-mer unstructured bridge. Thus, 
targets With large bridge regions are not necessarily poor 
reaction substrates. 
To determine Whether each riboZyme has speci?city for 
its intended target, TES reactions Were run using the rP-8/ 
4x-MD riboZyme With the 36-mer R carinii substrate at 13 
mM MgCl2, and the rP-8/4x riboZyme With the 38-mer 
DMPK mimic at 7 mM MgCl2, each at 440 C. (FIG. 6A). In 
US 7,211,661 B2 
17 
addition, the reaction Was run using the rP-8/4x-MD 
riboZyme at 7 mM MgCl2 and another reaction using the 
rP-8/4x riboZyme Was run at at 13 mM MgCl2 (data not 
shoWn). In these reactions, not even 5' cleavage products are 
observed, indicating that the riboZymes have some speci?c 
ity for their intended target substrates. Although the MgCl2 
concentration required for maximum activity di?cers for all 
the reactions, they all occur at or beloW that required (15 
mM) for maximum activity for the R carinii group I intron 
self-splicing reaction in vitro. While it Was knoWn that the 
sequence of REl could be modi?ed in reactions mimicking 
18 
the ?rst step of the self-splicing reaction (14, 20, 21), it Was 
previously not knoWn that all three recognition elements are 
modi?able. That these recognition elements completely 
specify binding and reactivity indicates that they are the 
primary determinants of speci?city betWeen the riboZyme 
and its substrate. In addition, bridging regions of di?cerent 
sequences and lengths (l, 3, 20, and 28 nucleotides) have 
been excised, indicating that perhaps a 3' G in the bridging 
region might be the only sequence requirement for the 
excised segment. 
SEQUENCE LISTING 
SEQ ID NO 1 
LENGTH: 33 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Chemically synthesized 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (13) .. (18) 
compared to P-8/4x 
OTHER INFORMATION: Represent altered recognition elements as 
<400> SEQUENCE: l 
cacgccgctt tcgggaacct ctatagtgag tcg 33 
<2 10> SEQ ID NO 2 
<2ll> LENGTH: 33 
<2 12> TYPE: DNA 
<2 13> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<220> FEATURE: 
<22l> NAME/KEY: miscifeature 
<222> LOCATION: (15)..(21) 
<223> OTHER INFORMATION: Represent altered recognition elements as 
compared to P-8/4x 
<400> SEQUENCE: 2 
cgactcacta tagaggttcc cgaaagcggc gtg 33 
<2 10> SEQ ID NO 3 
<2ll> LENGTH: 25 
<2 12> TYPE: DNA 
<2 13> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<220> FEATURE: 
<22l> NAME/KEY: miscifeature 
<222> LOCATION: (11)..(12) 
<223> OTHER INFORMATION: Represent altered recognition elements as 
compared to P-8/4x 
<400> SEQUENCE: 3 
ggtatagtct tgcctctttc gaaag 25 
SEQ ID NO 4 
LENGTH: 25 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Chemically synthesized 
FEATURE: 
NAME/KEY: miscifeature 
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-continued 
<222> LOCATION: ( 14 ) . . ( 15 ) 
<223> OTHER INFORMATION: Represent altered recognition elements as 
compared to P-8/4x 
<400> SEQUENCE: 4 
ctttcgaaag aggcaagact atacc 25 
<2 10> SEQ ID NO 5 
<2ll> LENGTH: 30 
<2 12> TYPE: DNA 
<2 13> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<220> FEATURE: 
<22l> NAME/KEY: miscifeature 
<222> LOCATION: ( 13 ) . . ( 15 ) 
<223> OTHER INFORMATION: Represent altered recognition elements as 
compared to P-8/4x 
<400> SEQUENCE: 5 
cgactcacta taggtgttcc cgaaagcggc 30 
<2 10> SEQ ID NO 6 
<2ll> LENGTH: 30 
<2 12> TYPE: DNA 
<2 13> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<220> FEATURE: 
<22l> NAME/KEY: miscifeature 
<222> LOCATION: ( l6 ) . . ( l8 ) 
<223> OTHER INFORMATION: Represent altered recognition elements as 
compared to P-8/4x 
<400> SEQUENCE: 6 
gccgctttcg ggaacaccta tagtgagtcg 30 
<2 10> SEQ ID NO 7 
<2ll> LENGTH: 12 
<2 12> TYPE: RNA 
<2 13> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: 7 
augacugugc uc l2 
<2 10> SEQ ID NO 8 
<2ll> LENGTH: 10 
<2 12> TYPE: RNA 
<2 13> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chenically synthesized 
<400> SEQUENCE: 8 
augacugcuc l0 
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What is claimed is: 
1. A modi?ed trans-excision-splicing Group I riboZyme 
comprising at least tWo modi?able recognition elements, 
Wherein at least one of said recognition elements is comple 
mentary to non-native target RNA sequence Within a sub 
strate having a 5' and 3' end and at least one of said 
recognition elements stabilizes binding of the riboZyme to a 
trans-excision splicing (TES) reaction intermediate product, 
and Wherein the riboZyme initiates a ?rst catalytic step in the 
absence of a guanosine cofactor and catalyZes a sequence 
speci?c excision of the non-native target RNA sequence, 
thereby forming a ?rst intermediate comprising the 5' end of 
the substrate and a second intermediate comprising the 3' 
end of the substrate, each intermediate having a 5' and 3' end, 
and splices the 3' end of the ?rst intermediate to the 
guanosine of the 5' end of the second intermediate created by 
the excision. 
2. The riboZyme of claim 1 Wherein the non-native target 
sequence is a single nucleotide. 
3. The riboZyme of claim 1 Wherein the non-native 
sequence comprises a premature stop codon. 
4. The riboZyme of claim 1 Wherein the non-native 
sequence comprises a frameshift mutation. 
5. The riboZyme of claim 1 Wherein the at least one 
recognition element is complementary to the triplet expan 
sion associated With Muscular Dystrophy. 
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6. The riboZyme of claim 5 Wherein the riboZyme 
removes the triplet expansion region involved in Muscular 
Dystrophy. 
7. The riboZyme of claim 1 Wherein the riboZyme is a 
modi?ed R carinii riboZyme. 
8. An expression cassette comprising a promoter oper 
ably-linked to a nucleotide sequence encoding a trans 
excision-splicing Group 1 riboZyme comprising at least tWo 
modi?able recognition elements, Wherein at least one of said 
recognition elements is complementary to non-native target 
RNA sequence Within a substrate and at least one of said 
recognition elements stabiliZes binding of the riboZyme to a 
trans-excision splicing (TES) reaction intermediate product, 
and Wherein the riboZyme initiates a ?rst catalytic step in the 
absence of a guanosine cofactor and catalyZes a sequence 
speci?c excision of the non-native target RNA sequence, 
thereby forming a ?rst intermediate comprising the 5' end of 
the substrate and a second intermediate comprising the 3' 
end of the substrate, each intermediate having a 5' and 3' end 
and splices the 3' end of the ?rst intermediate created by the 
excision to the guanosine of the 5' end of the second 
intermediate created by the excision. 
